Multiple Myeloma
Show Only Open Trials
1.
A Phase 3, Randomized Open Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma (ELOQUENT - 1)
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Protocol ID: BMS CA204006
2.
Lenalidomide, Bortezomib and Dexamethasone vs High-Dose Treatment with Peripheral Stem Cell Transplant in Myeloma Patients Up to Age 65
- Study Status: Open to Enrollment
- Sponsor: Dana Farber Cancer Institute
- Disease Status and/or Stage: Untreated Multiple Myeloma
3.
MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagnosed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Millennium
- Disease Status and/or Stage: Untreated Multiple Myeloma
- Protocol ID: C16014
4.
A Phase Ib/IIa Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma
- Study Status: Open to Enrollment
- Sponsor: Memorial Sloan-Kettering Cancer Center
- Disease Status and/or Stage: Relapsed or Refractory Lymphoma and Multiple Myeloma
5.
A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
- Study Status: Open to Enrollment
- Sponsor: Multiple Myeloma Research Foundation
- Disease Status and/or Stage: Untreated Multiple Myeloma
6.
A Phase 3, Randomized Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Untreated Multiple Myeloma
- Protocol ID: BMS - CA204006
7.
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Amgen
- Disease Status and/or Stage: Newly Diagnosed Multiple Myeloma
8.
Protocol FRF4998g: An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients with Relapsed or Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Genentech
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
- Protocol ID: FRF4998g
9.
A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Mutliple Myeloma
10.
Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed/Refractory Multiple Myeloma
11.
ENDEAVOR: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Onyx Pharmaceuticals
- Disease Status and/or Stage: Relapsed Multiple Myeloma
- Protocol ID: 2011-003 ENDEAVOR
12.
A Phase II Study of Dexamethasone (Decadron), Clarithromycin (Biaxin), and Pomalidomide (CC-4047) for Subjects with Relapsed or Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
13.
A Phase II Study of Sequential Carfilzomib, Clarithromycin, Lenalidomide, and Dexamethasone (Car-BiRD) Therapy for Subjects with Newly Diagnosed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Newly Diagnosed Multiple Myeloma; No Previous Treatment
14.
BMS CA204007: A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Multiple Multiple and Normal Renal Function, Severe Renal Impairment, or on Dialysis
- Protocol ID: BMS CA204007
15.
A Prospective Study of Optimally Matched-IPA Targeted Haplo-cord Transplantation
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
